综述与专题评论

应用微生物制剂缓解高草酸尿症的研究进展

  • 许明月 ,
  • 谭卓铭 ,
  • 王光强 ,
  • 熊智强 ,
  • 宋馨 ,
  • 杨昳津 ,
  • 张汇 ,
  • 艾连中 ,
  • 夏永军
展开
  • (上海理工大学 健康科学与工程学院,上海食品微生物工程研究中心,上海,200000)
硕士研究生(夏永军教授为通信作者,E-mail:dreamup@126.com)

收稿日期: 2022-11-24

  修回日期: 2023-01-04

  网络出版日期: 2023-06-30

基金资助

国家杰出青年科学基金项目(32025029);2021年度“中国食品科学技术学会食品科技基金-伊利健康科学基金”项目(2021-Y06);上海市教育委员会科研创新计划项目(2101070007800120);上海食品微生物工程技术研究中心项目(19DZ2281100)

Research progress on the application of microbial agents to alleviate hyperoxaluria

  • XU Mingyue ,
  • TAN Zhuoming ,
  • WANG Guangqiang ,
  • XIONG Zhiqiang ,
  • SONG Xin ,
  • YANG Yijin ,
  • ZHANG Hui ,
  • AI Lianzhong ,
  • XIA Yongjun
Expand
  • (Shanghai Engineering Research Center of Food Microbiology, School of Health Science and Engineering, University of Shanghai for Science and Technology, Shanghai 200000, China)

Received date: 2022-11-24

  Revised date: 2023-01-04

  Online published: 2023-06-30

摘要

草酸在人体内过度积累会导致高草酸尿症且易引发肾结石,目前尚无特效药物能够缓解高草酸尿症。肠道中存在草酸降解功能的微生物,可以通过多种途径降解人体内的草酸。肠-肾轴途径表明,正常个体的肠道微生物多样性和草酸降解菌的丰度显著高于高草酸尿症患者,所以增加患者肠道中的草酸降解微生物是缓解该症的潜在方法。具有降解草酸功能的产草酸甲酸杆菌、乳杆菌、链球菌和双歧杆菌等菌株已广泛用于人体内。文章总结了治疗高草酸尿症的微生物制剂及其缓解机制,包括粪便中的功能菌群、益生菌、基因工程菌等,以期为利用微生物制剂缓解高草酸尿症的相关研究提供理论参考。

本文引用格式

许明月 , 谭卓铭 , 王光强 , 熊智强 , 宋馨 , 杨昳津 , 张汇 , 艾连中 , 夏永军 . 应用微生物制剂缓解高草酸尿症的研究进展[J]. 食品与发酵工业, 2023 , 49(11) : 288 -297 . DOI: 10.13995/j.cnki.11-1802/ts.034414

Abstract

Excessive accumulation of oxalate in the human body will lead to hyperoxaluria, which is easy to cause kidney stones. At present, there are no specific drugs can alleviate hyperoxaluria, but there are oxalate-degrading microorganisms in the intestine that can degrade oxalate in the body through various pathways. The gut-kidney axis pathway indicated that the gut microbial diversity and the abundance of oxalate-degrading bacteria are significantly higher in normal human than those in patients with hyperoxaluria, so increasing the oxalate-degrading microorganisms in the gut of patients is a potential way to alleviate the disease. Strains of Oxalobacter formigenes, Lactobacillus, Streptococcus and Bifidobacterium with oxalate degrading function have been widely used in vivo. This article summarizes the microbial agent and mechanisms of alleviation for the treatment of hyperoxaluria, including functional flora in feces, probiotics, genetically engineered bacteria, in order to provide theoretical reference for the research on the treatment of hyperoxaluria with probiotics.

参考文献

[1] LIU M H, DEVLIN J C, HU J Y, et al.Microbial genetic and transcriptional contributions to oxalate degradation by the gut microbiota in health and disease[J].eLife, 2021, 10:e63642.
[2] WITTING C, LANGMAN C B, ASSIMOS D, et al.Pathophysiology and treatment of enteric hyperoxaluria[J].Clinical Journal of the American Society of Nephrology, 2021, 16(3):487-495.
[3] LIESKE J C, MEHTA R A, MILLINER D S, et al.Kidney stones are common after bariatric surgery[J].Kidney International, 2015, 87(4):839-845.
[4] MITCHELL T, KUMAR P, REDDY T, et al.Dietary oxalate and kidney stone formation[J].American Journal of Physiology.Renal Physiology, 2019, 316(3):F409-F413.
[5] CIL O, CHU T, LEE S J, et al.Small-molecule inhibitor of intestinal anion exchanger SLC26A3 for treatment of hyperoxaluria and nephrolithiasis[J].JCI Insight, 2022, 7(13):e153359.
[6] CANALES B K, HATCH M.Kidney stone incidence and metabolic urinary changes after modern bariatric surgery:Review of clinical studies, experimental models, and prevention strategies[J].Surgery for Obesity and Related Diseases:Official Journal of the American Society for Bariatric Surgery, 2014, 10(4):734-742.
[7] HOLMES R P, KNIGHT J, ASSIMOS D G.Lowering urinary oxalate excretion to decrease calcium oxalate stone disease[J].Urolithiasis, 2016, 44(1):27-32.
[8] XU L H R, ADAMS-HUET B, POINDEXTER J R, et al.Temporal changes in kidney stone composition and in risk factors predisposing to stone formation[J].The Journal of Urology, 2017, 197(6):1 465-1 471.
[9] LIESKE J C, PEÑA DE LA VEGA L S, SLEZAK J M, et al.Renal stone epidemiology in Rochester, Minnesota:An update[J].Kidney International, 2006, 69(4):760-764.
[10] LAMINSKI N A, MEYERS A M, KRUGER M, et al.Hyperoxaluria in patients with recurrent calcium oxalate calculi:Dietary and other risk factors[J].British Journal of Urology, 1991, 68(5):454-458.
[11] HOLMES R P, GOODMAN H O, ASSIMOS D G.Contribution of dietary oxalate to urinary oxalate excretion[J].Kidney International, 2001, 59(1):270-276.
[12] WEI Z T, CUI Y Q, TIAN L, et al.Probiotic Lactiplantibacillus plantarum N-1 could prevent ethylene glycol-induced kidney stones by regulating gut microbiota and enhancing intestinal barrier function[J].FASEB Journal:Official Publication of the Federation of American Societies for Experimental Biology, 2021, 35(11):e21937.
[13] HATCH M, GJYMISHKA A, SALIDO E C, et al.Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter[J].American Journal of Physiology.Gastrointestinal and Liver Physiology, 2011, 300(3):G461-G469.
[14] HATCH M, CORNELIUS J, ALLISON M, et al.Oxalobacter sp.reduces urinary oxalate excretion by promoting enteric oxalate secretion[J].Kidney International, 2006, 69(4):691-698.
[15] MIKAMI K, AKAKURA K, TAKEI K, et al.Association of absence of intestinal oxalate degrading bacteria with urinary calcium oxalate stone formation[J].International Journal of Urology, 2003, 10(6):293-296.
[16] SIDHU H, ALLISON M J, MAY CHOW J O, et al.Rapid reversal of hyperoxaluria in a rat model after probiotic administration of oxalobacter formigenes[J].The Journal of Urology, 2001, 166(4):1 487-1 491.
[17] SIENER R, BANGEN U, SIDHU H, et al.The role of Oxalobacter formigenes colonization in calcium oxalate stone disease[J].Kidney International, 2013, 83(6):1 144-1 149.
[18] ALLISON M J, DAWSON K A, MAYBERRY W R, et al.Oxalobacter formigenes Gen.nov., sp.nov.:Oxalate-degrading anaerobes that inhabit the gastrointestinal tract[J].Archives of Microbiology, 1985, 141(1):1-7.
[19] TURRONI S, VITALI B, BENDAZZOLI C, et al.Oxalate consumption by lactobacilli:Evaluation of oxalyl‐CoA decarboxylase and formyl‐CoA transferase activity in Lactobacillus acidophilus[J].Journal of Applied Microbiology, 2007, 103(5):1 600-1 609.
[20] HOKAMA S, HONMA Y, TOMA C, et al.Oxalate-degrading Enterococcus faecalis[J].Microbiology and Immunology, 2000, 44(4):235-240.
[21] TURRONI S, BENDAZZOLI C, DIPALO S C, et al.Oxalate-degrading activity in Bifidobacterium animalis subsp.lactis:Impact of acidic conditions on the transcriptional levels of the oxalyl coenzyme A (CoA) decarboxylase and formyl-CoA transferase genes[J].Applied and Environmental Microbiology, 2010, 76(16):5 609-5 620.
[22] FEDERICI F, VITALI B, GOTTI R, et al.Characterization and heterologous expression of the oxalyl coenzyme A decarboxylase gene from Bifidobacterium lactis[J].Applied and Environmental Microbiology, 2004, 70(9):5 066-5 073.
[23] HOKAMA S, TOMA C, IWANAGA M, et al.Oxalate-degrading Providencia rettgeri isolated from human stools[J].International Journal of Urology:Official Journal of the Japanese Urological Association, 2005, 12(6):533-538.
[24] FATAHI S, HOSSEINI A, SOHOULI M H, et al.Effects of probiotic supplementation on abdominal pain severity in pediatric patients with irritable bowel syndrome:A systematic review and meta-analysis of randomized clinical trials[J].World Journal of Pediatrics, 2022, 18(5):320-332.
[25] ALGIERI F, GARRIDO-MESA J, VEZZA T, et al.Intestinal anti-inflammatory effects of probiotics in DNBS-colitis via modulation of gut microbiota and microRNAs[J].European Journal of Nutrition, 2021, 60(5):2 537-2 551.
[26] ASO Y, AKAZA H, KOTAKE T, et al.Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial.The BLP Study Group[J].European Urology, 1995, 27(2):104-109.
[27] CAMPIERI C, CAMPIERI M, BERTUZZI V, et al.Reduction of oxaluria after an oral course of lactic acid bacteria at high concentration[J].Kidney International, 2001, 60(3):1 097-1 105.
[28] OKOMBO J, LIEBMAN M.Probiotic-induced reduction of gastrointestinal oxalate absorption in healthy subjects[J].Urological Research, 2010, 38(3):169-178.
[29] LIESKE J C, GOLDFARB D S, DE SIMONE C, et al.Use of a probioitic to decrease enteric hyperoxaluria[J].Kidney International, 2005, 68(3):1 244-1 249.
[30] MURPHY C, MURPHY S, O’BRIEN F, et al.Metabolic activity of probiotics—Oxalate degradation[J].Veterinary Microbiology, 2009, 136(1-2):100-107.
[31] ZHENG L, KELLY C J, COLGAN S P.Physiologic hypoxia and oxygen homeostasis in the healthy intestine.A Review in the Theme:Cellular Responses to Hypoxia[J].American Journal of Physiology.Cell Physiology, 2015, 309(6):C350-C360.
[32] FURNESS J B, CALLAGHAN B P, RIVERA L R, et al.The enteric nervous system and gastrointestinal innervation:Integrated local and central control[J].Advances in Experimental Medicine and Biology, 2014, 817:39-71.
[33] LEVY M, BLACHER E, ELINAV E.Microbiome, metabolites and host immunity[J].Current Opinion in Microbiology, 2017, 35:8-15.
[34] LYNCH S V, PEDERSEN O.The human intestinal microbiome in health and disease[J].The New England Journal of Medicine, 2016, 375(24):2 369-2 379.
[35] MEIJERS B K I, EVENEPOEL P.The gut-kidney axis:Indoxyl sulfate, p-cresyl sulfate and CKD progression[J].Nephrology Dialysis Transplantation, 2011, 26(3):759-761.
[36] STERN J M, MOAZAMI S, QIU Y P, et al.Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers[J].Urolithiasis, 2016, 44(5):399-407.
[37] TICINESI A, NOUVENNE A, CHIUSSI G, et al.Calcium oxalate nephrolithiasis and gut microbiota:Not just a gut-kidney axis.A nutritional perspective[J].Nutrients, 2020, 12(2):548.
[38] TICINESI A, MILANI C, GUERRA A, et al.Understanding the gut-kidney axis in nephrolithiasis:An analysis of the gut microbiota composition and functionality of stone formers[J].Gut, 2018, 67(12):2 097-2 106.
[39] TANG R Q, JIANG Y H, TAN A H, et al.16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones[J].Urolithiasis, 2018, 46(6):503-514.
[40] ZHU H, CAO C J, WU Z C, et al.The probiotic L.casei Zhang slows the progression of acute and chronic kidney disease[J].Cell Metabolism, 2021, 33(10):1 926-1 942.
[41] FELIZARDO R J F, WATANABE I K M, DARDI P, et al.The interplay among gut microbiota, hypertension and kidney diseases:The role of short-chain fatty acids[J].Pharmacological Research, 2019, 141:366-377.
[42] PLATA C, CRUZ C, CERVANTES L G, et al.The gut microbiota and its relationship with chronic kidney disease[J].International Urology and Nephrology, 2019, 51(12):2 209-2 226.
[43] CAGGIANO G, COSOLA C, LEO V D, et al.Microbiome modulation to correct uremic toxins and to preserve kidney functions[J].Current Opinion in Nephrology and Hypertension, 2020, 29(1):49-56.
[44] MILLER A W, OAKESON K F, DALE C, et al.Microbial community transplant results in increased and long-term oxalate degradation[J].Microbial Ecology, 2016, 72(2):470-478.
[45] HAN C, JIANG Y H, LI W, et al.Astragalus membranaceus and Salvia miltiorrhiza ameliorates cyclosporin A-induced chronic nephrotoxicity through the “gut-kidney axis”[J].Journal of Ethnopharmacology, 2021, 269:113768.
[46] LIU Y, JIN X, MA Y C, et al.Short-chain fatty acids reduced renal calcium oxalate stones by regulating the expression of intestinal oxalate transporter SLC26A6[J].mSystems, 2021, 6(6):e0104521.
[47] SOLIMAN N R, EFFAT B A M, MEHANNA N S, et al.Activity of probiotics from food origin for oxalate degradation[J].Archives of Microbiology, 2021, 203(8):5 017-5 028.
[48] REN Z H, PAN C L, JIANG L Y, et al.Oxalate-degrading capacities of lactic acid bacteria in canine feces[J].Veterinary Microbiology, 2011, 152(3-4):368-373.
[49] KWAK C, JEONG B C, KU J H, et al.Prevention of nephrolithiasis by Lactobacillus in stone-forming rats:A preliminary study[J].Urological Research, 2006, 34(4):265-270.
[50] GOMATHI S, SASIKUMAR P, ANBAZHAGAN K, et al.Oral administration of indigenous oxalate degrading lactic acid bacteria and quercetin prevents calcium oxalate stone formation in rats fed with oxalate rich diet[J].Journal of Functional Foods, 2015, 17:43-54.
[51] MEHRA Y, RAJESH N G, VISWANATHAN P.Analysis and characterization of Lactobacillus paragasseri and Lacticaseibacillus paracasei:Two probiotic bacteria that can degrade intestinal oxalate in hyperoxaluric rats[J].Probiotics and Antimicrobial Proteins, 2022, 14(5):854-872.
[52] MEHRA Y, VISWANATHAN P.High-quality whole-genome sequence analysis of Lactobacillus paragasseri UBLG-36reveals oxalate-degrading potential of the strain[J].PLoS One, 2021, 16(11):e0260116.
[53] SASIKUMAR P, GOMATHI S, ANBAZHAGAN K, et al.Recombinant Lactobacillus plantarum expressing and secreting heterologous oxalate decarboxylase prevents renal calcium oxalate stone deposition in experimental rats[J].Journal of Biomedical Science, 2014, 21(1):86.
[54] PAUL E, ALBERT A, PONNUSAMY S, et al.Designer probiotic Lactobacillus plantarum expressing oxalate decarboxylase developed using group II intron degrades intestinal oxalate in hyperoxaluric rats[J].Microbiological Research, 2018, 215:65-75.
[55] ZHAO C M, YANG H, ZHU X J, et al.Oxalate-degrading enzyme recombined lactic acid bacteria strains reduce hyperoxaluria[J].Urology, 2018, 113:253.e1-253.e7.
[56] AFKARI R, FEIZABADI M M, ANSARI-MOGHADAM A, et al.Simultaneous use of oxalate-degrading bacteria and herbal extract to reduce the urinary oxalate in a rat model:A new strategy[J].International Braz J Urol:Official Journal of the Brazilian Society of Urology, 2019, 45(6):1 249-1 259.
[57] ZAMPINI A, NGUYEN A H, ROSE E, et al.Defining dysbiosis in patients with urolithiasis[J].Scientific Reports, 2019, 9(1):1-13.
[58] WANG L F, ZHANG J C, GUO Z, et al.Effect of oral consumption of probiotic Lactobacillus planatarum P-8 on fecal microbiota, SIgA, SCFAs, and TBAs of adults of different ages[J].Nutrition, 2014, 30(7-8):776-783.
[59] SIES H.Oxidative stress:A concept in redox biology and medicine[J].Redox Biology, 2015, 4:180-183.
[60] SCHEID C, KOUL H, HILL W A, et al.Oxalate toxicity in LLC-PK1 cells:Role of free radicals[J].Kidney International, 1996, 49(2):413-419.
[61] DAVALOS M, KONNO S, ESHGHI M, et al.Oxidative renal cell injury induced by calcium oxalate crystal and renoprotection with antioxidants:A possible role of oxidative stress in nephrolithiasis[J].Journal of Endourology, 2010, 24(3):339-345.
[62] KHAND F D, GORDGE M P, ROBERTSON W G, et al.Mitochondrial superoxide production during oxalate-mediated oxidative stress in renal epithelial cells[J].Free Radical Biology and Medicine, 2002, 32(12):1 339-1 350.
[63] ITOH Y, YASUI T, OKADA A, et al.Preventive effects of green tea on renal stone formation and the role of oxidative stress in nephrolithiasis[J].The Journal of Urology, 2005, 173(1):271-275.
[64] LI C Y, DENG Y L, SUN B H.Taurine protected kidney from oxidative injury through mitochondrial-linked pathway in a rat model of nephrolithiasis[J].Urological Research, 2009, 37(4):211-220.
[65] KULLISAAR T, ZILMER M, MIKELSAAR M, et al.Two antioxidative lactobacilli strains as promising probiotics[J].International Journal of Food Microbiology, 2002, 72(3):215-224.
[66] WANG Y, WU Y P, WANG Y Y, et al.Antioxidant properties of probiotic bacteria[J].Nutrients, 2017, 9(5):521.
[67] SASIKUMAR P, GOMATHI S, ANBAZHAGAN K, et al.Genetically engineered Lactobacillus plantarum WCFS1 constitutively secreting heterologous oxalate decarboxylase and degrading oxalate under in vitro[J].Current Microbiology, 2014, 69(5):708-715.
[68] KOLANDASWAMY A, GEORGE L, SADASIVAM S.Heterologous expression of oxalate decarboxylase in Lactobacillus plantarum NC8[J].Current Microbiology, 2009, 58(2):117-121.
[69] SASIKUMAR P, GOMATHI S, ANBAZHAGAN K, et al.Secretion of biologically active heterologous oxalate decarboxylase (OxdC) in Lactobacillus plantarum WCFS1 using homologous signal peptides[J].BioMed Research International, 2013, 2013:280432.
[70] ANBAZHAGAN K, SASIKUMAR P, GOMATHI S, et al.In vitro degradation of oxalate by recombinant Lactobacillus plantarum expressing heterologous oxalate decarboxylase[J].Journal of Applied Microbiology, 2013, 115(3):880-887.
[71] LUBKOWICZ D, HORVATH N G, JAMES M J, et al.An engineered bacterial therapeutic lowers urinary oxalate in preclinical models and in silico simulations of enteric hyperoxaluria[J].Molecular Systems Biology, 2022, 18(3):e10539.
[72] LANGMAN C B, GRUJIC D, PEASE R M, et al.A double-blind, placebo controlled, randomized phase 1 cross-over study with ALLN-177, an orally administered oxalate degrading enzyme[J].American Journal of Nephrology, 2016, 44(2):150-158.
[73] LINGEMAN J E, PAREEK G, EASTER L, et al.ALLN-177, oral enzyme therapy for hyperoxaluria[J].International Urology and Nephrology, 2019, 51(4):601-608.
[74] LEE E, JEONG B C, PARK Y H, et al.Expression of the gene encoding oxalate decarboxylase from Bacillus subtilis and characterization of the recombinant enzyme[J].BMC Research Notes, 2014, 7:598.
文章导航

/